AP NEWS

Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Updated Deal Trends, Players and Financials - ResearchAndMarkets.com

November 27, 2018

DUBLIN--(BUSINESS WIRE)--Nov 27, 2018--The “Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2010-2018: Deal trends, players and financials” report has been added to ResearchAndMarkets.com’s offering.

The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

Monoclonal antibodies Murine mAb Chimeric mAb Humanized mAb Human aAb

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

In addition, a comprehensive appendix is provided organized by Cancer monoclonal antibody partnering company A-Z, deal type definitions and Cancer monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Cancer monoclonal antibody partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cancer monoclonal antibody technologies and products.

Report scope

Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2012 Analysis of cancer monoclonal antibody deal structure Access to headline, upfront, milestone and royalty data Access to over 360 cancer monoclonal antibody deal records The leading cancer monoclonal antibody deals by value since 2012

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

Company A-Z Headline value Stage of development at signing Deal component type Specific oncology therapy target Monoclonal antibody type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking

2.1. Introduction

2.2. Cancer monoclonal antibody partnering over the years

2.3. Most active Cancer monoclonal antibody dealmakers

2.4. Cancer monoclonal antibody partnering by deal type

2.5. Cancer monoclonal antibody partnering by therapy area

2.6. Deal terms for Cancer monoclonal antibody partnering

2.6.1 Cancer monoclonal antibody partnering headline values

2.6.2 Cancer monoclonal antibody deal upfront payments

2.6.3 Cancer monoclonal antibody deal milestone payments

2.6.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading Cancer monoclonal antibody deals

3.1. Introduction

3.2. Top Cancer monoclonal antibody deals by value

Chapter 4 - Most active Cancer monoclonal antibody dealmakers

4.1. Introduction

4.2. Most active Cancer monoclonal antibody dealmakers

4.3. Most active Cancer monoclonal antibody partnering company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

5.1. Introduction

5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

Monoclonal antibodies

Chimeric mAb

Humanized mAb

Human mAb

Murine mAb

Chapter 7 - Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking

Appendices

Appendix 1 - Cancer monoclonal antibody deals by company A-Z

Appendix 2 - Cancer monoclonal antibody deals by stage of development

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

Formulation

Appendix 3 - Cancer monoclonal antibody deals by deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Co-promotion

CRADA

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Loan

Manufacturing

Marketing

Material transfer

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Appendix 4 - Cancer monoclonal antibody deals by therapy area

Appendix 5 - Deal type definitions

For more information about this report visit https://www.researchandmarkets.com/research/p6snlk/global_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181127005755/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Oncology Drugs,Biopharmaceuticals

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/27/2018 01:34 PM/DISC: 11/27/2018 01:34 PM

http://www.businesswire.com/news/home/20181127005755/en

AP RADIO
Update hourly